VistaGen Therapeutics, Inc Blog | Talkmarkets | Page 1
No data available
No data available

People who follow this stock (29)

View All

Latest Posts

About This Stock More About This Stock
VistaGen Therapeutics Announces Positive Meeting With FDA Regarding Pivotal Phase 3 Study Of PH94B For Acute Treatment Of Anxiety In Patients With Social Anxiety Disorder
Article By: TalkMarkets Newswire
Thursday, July 23, 2020 9:00 AM EDT
VistaGen and the FDA reached consensus on key aspects of a unique initial pivotal Phase 3 clinical trial of PH94B involving a single-event, laboratory-simulated public speaking challenge in adult patients with SAD.
In this article: VTGN Also: IMMP, ARTX, SAGE, RLMD, BHVN
Read
Week In Review: VistaGen Out-Licenses China/Asia Rights For Novel Anxiety Drug To EverInsight In $177 Million Deal
Article By: ChinaBio® Today
Saturday, June 27, 2020 2:00 PM EDT
VistaGen of South San Francisco out-licensed China/Southeast Asia rights for a novel anxiety treatment to EverInsight Therapeutics, a China in-licensing company, in a $177 million agreement.
In this article: VTGN Also: AGEN, HCM, GTHX, SEQUX, GILD, MRK
Read
VistaGen Therapeutics And EverInsight Therapeutics Enter Strategic Collaboration To Develop And Commercialize PH94B For Anxiety Disorders In Greater China, South Korea And Southeast Asia
Article By: TalkMarkets Newswire
Thursday, June 25, 2020 8:03 AM EDT
The collaboration is intended to support Phase 3 development and commercialization of PH94B in key Asian markets. The agreement includes a $5 million upfront payment and development and commercial milestones up to $172 million.
In this article: VTGN Also: ARTX, SAGE, RLMD, BHVN
Read
E VistaGen Therapeutics: Interesting Prospects
Article By: Terry Chrisomalis
Tuesday, October 3, 2017 10:54 AM EDT
VistaGen's drug AV-101 has breakthrough potential for treatment of depression and other indications.
In this article: VTGN Also: AGN
Read
Let's Talk Depression And How To Play The NMDA Buzz
Article By: Jason Napodano
Thursday, April 6, 2017 12:21 PM EDT
I think VistaGen's stock has tremendous upside potential that today's price. The company is likely to raise cash at some point over the next several months.
In this article: VTGN Also: AGN, JNJ, SAGE
Read
All Posts

PARTNER HEADLINES

Latest Tweets for $VTGN

No tweets yet!

$VTGN

Comments Status Updates
VistaGen Therapeutics: Interesting Prospects
Alexis Renault • 10/5/2017 7:43:59 PM

Thanks Terry! Will take a closer look at $VTGN.

VistaGen Therapeutics: Interesting Prospects
Derek Snyder • 10/4/2017 9:07:54 AM

Your argument for acquisition sounds convincing, but I wonder if there have been any such overtures. Know if that's the case? Which companies would be the most likely to target #Vistagen? $VTGN.

VistaGen Therapeutics: Interesting Prospects
David M. Green • 10/4/2017 2:43:18 AM

Looks promising. Sounds like $VTGN should be getting more love from investors.

VistaGen Therapeutics: Interesting Prospects
Bill Johnson • 10/3/2017 10:34:18 PM

Definitely sounds like some interesting prospects indeed! $VTGN

1 to 4 of 4 comments